Percentage of cases that required the use of nalaxone or flumazenil for medication overdose.
Opioid and/or benzodiazepine administration can lead to respiratory depression, brain damage, and even death. Judicious use of opioids for patients that have planned extubation at end of case can avoid use of reversal agents and their side effects. For patients not meeting extubation requirements due to opioids or benzodiazepines, waiting until the effects wear off is preferable to reversal administration.
Anesthesia Start to Anesthesia End
All cases in which opioids or benzodiazepines were administered during the intraoperative period.
Administration of naloxone or flumazenil was not required for the case.
Special Considerations: If naloxone was given as an infusion AND as a bolus, the case is flagged due to the bolus. If naloxone is only given as an infusion, then the case is still evaluated for flumazenil. Patients receiving naloxone as in infusion indicate naloxone is being infused for pruritus for neuraxial technique.
MED 01 is an outcome measure that identifies intraoperative medication overdose by monitoring the administration of opioids and/or benzodiazepines and the administration of their reversals: flumanzenil and naloxone. Flumazenil is given for benzodiazepine overdose. Nalaxone is given for opioid overdose. The time period for this measure is Anesthesia Start to Anesthesia End. PACU time is not included currently.
Algorithm for determining Case Duration:
The provider who is signed in for the longest portion of the case between Case Start and Case End. See ‘Other Measure Build Details’ section of this specification to view the algorithm used for determining case duration.
|Date Reviewed||Reviewer||Institution||Summary||QC Vote|
Univeristy of Washington
|Pending||Multiple||Remove Flumazenil, add Methadone and extend to PACU end.|